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Abstract
Background: Checkpoint inhibitor immunotherapy is becoming an effective treatment modality for an increasing
number of malignancies. As a result, autoinflammatory side-effects are also being observed more commonly in the
clinic. We are currently unable to predict which patients will develop more severe toxicities associated with these
treatment regimens.
Case presentation: We present a patient with stage IV melanoma that developed rapid onset autoimmune type 1
diabetes (T1D) in response to combination ipilimumab and nivolumab immunotherapy. At the time of the patient’s
presentation with diabetes ketoacidosis, a confirmed anti-GAD antibody seroconversion was noted. Longer-term
follow-up of this patient has demonstrated a durable complete response based on PET CT imaging along with a
persistently undetectable C-peptide level. Single nucleotide polymorphism gene sequencing and HLA risk allele analysis
has revealed the patient to lack any established genetic predisposition to the development of autoimmune T1D.
Conclusions: While larger studies are necessary to better understand the role of genetic risk factors for the development
of autoimmune toxicities in those patients undergoing checkpoint inhibitor immunotherapy, these results suggest that
pre-screening patients for known T1D risk alleles may not be indicated. Additional investigation is needed to determine
whether an approach such as T cell receptor clonotypic analysis to identify the presence of autoreactive T cell clones
may be an effective approach for predicting which patients are at risk for the development of autoinflammatory toxicities
while undergoing checkpoint inhibitor immunotherapy.
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Background
Recent developments in cancer immunotherapy have led
to the widespread use of immune checkpoint inhibitors
for the management of advanced melanoma. This includes
ipilimumab, a human IgG1 monoclonal antibody that
blocks the negative checkpoint regulator CTLA-4 on
the surface of activated T cells [1]. Additional checkpoint
inhibitors designed to counteract the ability of tumor cells
to dampen the host immune response include nivolumab
and pembrolizumab, both IgG4 monoclonal antibodies
that target the negative regulatory T cell surface receptor,
PD-1 [2]. Each of these agents have been shown to signifi-
cantly prolong overall survival in patients with advanced
melanoma in phase III clinical trials [3, 4] and, in the case
of the anti-PD-1 antibodies, are now being utilized in the
treatment of other solid tumors reflected by the recent
FDA approvals for their use in non-small cell lung cancer,
renal cell carcinoma, and head and neck squamous cell
carcinoma [5–7].
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Early in their development, it was recognized that these
immune checkpoint inhibitors were associated with a novel
syndrome of autoimmune or autoinflammatory side effects
[8]. These toxicities have become known as immune-
related adverse events (irAEs) and occur more frequently
when these agents are administered in combination
regimens. The incidence of grade 3/4 irAEs has been
reported in up to 23% of patients receiving ipilimumab,
14% of patients receiving nivolumab, and 54% of patients
undergoing treatment with the ipilimumab and nivolumab
combination regimen [3]. While several autoimmune con-
ditions have been reported in patients undergoing these
therapies, the most common irAEs include dermatitis,
enterocolitis, hepatitis, as well as various endocrinopathies
[2]. Depending on the pathway targeted, the more common
endocrinopathies include autoimmune hypothyroidism
often following a period of hyperthyroidism in the setting
of thyroiditis, as well as autoimmune lymphocytic hypo-
physitis, often manifesting as anterior panhypopituitarism.
Ipilimumab monotherapy at a dose of 3 mg/kg has been
associated with the condition of hypophysitis in 3-9% of
cases while the reported observed incidence increases to
12% in patients undergoing combinatorial checkpoint
immunotherapy [2, 9].
Although relatively uncommon, cases of autoimmune
diabetes, known as type 1 diabetes (T1D), have emerged
in association with use of the anti-PD1 antibody therapies
[10–15]. Herein, we report a case of fulminant T1D
manifesting as diabetic ketoacidosis concurrent with
autoimmune thyroiditis and acute adrenal insufficiency
occurring in a patient with advanced melanoma undergoing
combination nivolumab and ipilimumab immunotherapy.
To better understand the development of T1D in the
setting of combination anti-PD-1 and anti-CTLA-4 anti-
body therapy, we conducted a genetic risk analysis of this
patient based on single nucleotide polymorphism (SNP)
and HLA risk allele sequencing. We will review this experi-
ence in the context of other recent reports of immune
checkpoint inhibitor-induced T1D and discuss the implica-




Treatment-related side-effects were graded according to
the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE), version 4.0.
SNP analysis and GRS calculation
The patient’s PBMC-derived DNA sample was interrogated
at the University of Florida Diabetes Institute for 26 unique
SNP loci found to be associated with the pathogenesis of T1D
according to ImmunoBase (https://www.immunobase.org/).
The genetic risk score (GRS) was calculated as a sum of
each risk allele multiplied by its associated ln(Odds
Ratio (OR)) divided by the total number of risk alleles
tested producing a range from 0 (no susceptibility alleles)
to 1 (all susceptibility alleles) [16].
Case presentation
A 54 year-old male with no significant past medical history
was initially diagnosed with a cutaneous melanoma involv-
ing his left forearm in September 2012. He underwent local
resection and sentinel lymph node biopsy at an outside
institution with pathology showing an invasive melanoma
characterized by an ulcerated Clark level V lesion with a
Breslow thickness of 5.5 mm and 3 mitoses/mm2. A
sentinel lymph node biopsy was positive for 1 of 1 lymph
node with a 0.35 mm deposit of melanoma. A complete
lymph node dissection of the left axilla was performed
demonstrating no evidence of melanoma in any of 42
lymph nodes. He underwent surveillance imaging by
whole body PET CT through June of 2013 with no evi-
dence of disease recurrence.
In September of 2013, the patient noted development
of a subcutaneous nodule in his left upper extremity. On
examination, he was found to have unilateral swelling of
his left lower extremity and a palpable intra-muscular
mass. Fine-needle aspiration of the left upper extremity
nodule was performed and pathology was consistent with
melanoma. PET CT imaging performed in October of
2013 demonstrated a subcentimeter FDG avid lesion in
the left upper extremity correlating with the subcutaneous
nodule, as well as an intramuscular lesion in the left
gastrocnemius with marked FDG uptake and a focal
area of FDG uptake in the small intestine without a CT
correlate.
The patient was referred to our melanoma clinic for
further care in December of 2013. Repeat imaging with
PET CT performed at that time confirmed prior FDG
avid lesions involving the upper and lower extremities
along with the small bowel lesion (Fig. 1). Brain MRI
was negative. Molecular diagnostics performed on a tissue
sample identified the melanoma as BRAF and c-kit wild
type. The patient elected to enroll in the CheckMate-069
randomized, double blind clinical trial evaluating com-
bination ipilimumab and nivolumab therapy versus
ipilimumab monotherapy in previously untreated pa-
tients with advanced melanoma (NCT01927419). He
received his first infusion in January of 2014, returning
2 weeks later with a diffuse grade 3 skin rash, tachycardia,
and reports of hot flashes (Fig. 2). Laboratory analysis
indicated elevated levels of free triiodothyronine at
9.68 pg/mL (normal 2.20 – 3.80 pg/mL) and free thy-
roxine at 4.16 ng/dL (normal 0.52 – 1.21 ng/dL) in the
setting of a decreased thyroid stimulating hormone (TSH)
level of 0.06 uIU/mL (normal 0.34 – 5.66 uIU/mL). Anti-
microsomal antibodies were positive and his thyrotropin
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receptor antibody level was noted to be elevated at
4.74 IU/L (normal 0.00 – 1.75 IU/L). Autoimmune
thyroiditis was diagnosed prompting treatment with
prednisone and metoprolol while the rash was managed
with topical steroids.
Once his symptoms resolved and he was tapered off
systemic steroids, the second infusion was administered
approximately 6 weeks later. Three weeks following his
second dose of combination ipilimumab/nivolumab therapy,
routine laboratory analysis indicated a grade 2 hepato-
toxicity, attributed to treatment-induced autoimmune
hepatitis, as well as symptoms consistent with a grade 1
colitis. Testing for CMV reactivation was not performed. He
was treated with prednisone which was tapered as the trans-
aminitis resolved. At this time the patient was found to have
abnormally diminished levels of free triiodothyronine at
Fig. 1 PET CT Imaging of Patient Undergoing Combination Ipilimumab/Nivolumab Immunotherapy. a left arrow, mesenteric lesion. right arrow,
left upper extremity cutaneous lesion (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of
combination ipilimumab/nivolumab therapy. b (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose
of combination ipilimumab/nivolumab therapy, (3) 1 year following the third dose of combination ipilimumab/nivolumab therapy and treatment
discontinuation due to toxicity
Fig. 2 Time line of clinical events
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1.69 pg/mL and free levothyroxine at <0.25 ng/dL
along with an elevated TSH at 7.50 uIU/mL. Given his
hypothyroid state, his metoprolol was stopped and
therapy with levothyroxine was initiated.
Repeat imaging with PET CT in March of 2014 showed
complete resolution of the left upper extremity nodule
and small intestine lesions and decreased size and FDG
avidity of the left gastrocnemius lesion (Fig. 1). Diffuse
colitis was apparent on imaging. The patient continued to
report one to two loose stools a day throughout his
treatment course and his symptoms were managed with
loperamide in addition to the previous prednisone taper.
In May of 2014 the patient received his third infusion.
Two weeks later, he returned to the clinic with extreme
weakness, myalgias, nausea, and vomiting. His vitals
showed a blood pressure of 88/54 mmHg with a pulse of
121, and his laboratory analysis revealed profound hyper-
glycemia with an anion gap metabolic acidosis. Due to
concerns for new onset diabetic ketoacidosis with acute
adrenal insufficiency, he was transferred directly to the
medical intensive care unit. Intravenous fluids, insulin, and
methylprednisolone were initiated. His β-hydroxybutyrate
level was noted to be elevated at 0.40 mmol/L while his
ACTH was found to be undetectable and his cortisol level
was 3.5 μg/dL (normal 5.0 – 25.0 μg/dL). The patient’s
C-peptide was <0.1 ng/mL, and he was noted to have
elevated levels of anti-glutamic acid decarboxylase
(anti-GAD) antibodies during his hospitalization at
0.38 nmol/L (normal ≤0.02 nmol/L). The patient was
eventually transitioned from intravenous insulin to a
subcutaneous regimen, steroids were tapered to hydrocorti-
sone, and he was discharged to home after a 3-day admis-
sion. Notably, further studies on serum previously collected
per study protocol showed that the patient exhibited an
undetectable anti-GAD antibody titer 1 month prior to ini-
tiating treatment with combination ipilimumab/nivolumab
immunotherapy.
As the patient had demonstrated evidence of multiple
endocrinopathies, further evaluation of his pituitary function
was conducted. This included a prolactin of 6.51 ng/mL
(normal 2.64 – 13.13 ng/mL), LH of 3.8 mIU/mL (normal
1.4 – 7.7 mIU/mL), FSH of 17.8 mIU/mL (normal 1.3 –
19.3 mIU/mL), free thyroxine of 0.84 ng/dL (normal 0.52 –
1.21 ng/dL), testosterone of 64 ng/dL (normal > 300 ng/dL),
and free testosterone of 1.9 ng/dL (normal > 9 ng/dL).
A subsequent brain MRI performed with pituitary protocol
was unremarkable and unchanged compared with a base-
line study. An early morning Cosyntropin stimulation test
was conducted in October of 2014 following a 5 month
maintenance dosage of prednisone at 10 mg daily which
was tapered to discontinuation over a period of 6 weeks
prior to stimulation testing. Baseline testing of ACTH and
cortisol remained undetectable while the cortisol level post-
stimulation was inappropriately low at 1.8 microgram/dL
(normal 5.0 – 25.0 microgram/dL). Together, these findings
were felt to be consistent with hypophysitis.
In light of the multiple autoinflammatory toxicities,
the patient was removed from the study and placed on
surveillance comprised of a physical exam, lab assessment,
and PET CT imaging every 3 months in addition to der-
matologic surveillance every 6 months. Soon thereafter, it
was revealed that the patient had been randomized to the
combination ipilimumab and nivolumab immunotherapy
regimen. His follow-up exams continued to reveal a stable
1.1 cm nodule with low-level FDG avidity within the left
gastrocnemius muscle with no other evidence of disease
recurrence until September of 2014 when the left gastro-
cnemius lesion was no longer FDG avid. As of August
2016, the patient has been without evidence of melanoma
recurrence and continues on an insulin regimen with an
undetectable C-peptide level.
Conclusions
The exact mechanisms by which immune checkpoint
inhibitors induce autoimmunity and cause irAEs are
not fully understood. Recent research on anti-CTLA-4
associated hypophysitis suggests that local expression
of CTLA-4 in the pituitary leads to antibody binding
and activation of the complement pathway with subsequent
site-specific inflammation and tissue injury [17]. However,
this work is observational, and the exact pathophysiology of
other irAEs, including the possible role of complement-
mediated injury, remains elusive. It is suspected that check-
point inhibitors interfere with peripheral tolerance and
potentiate autoimmune disorders in genetically predisposed
individuals [5]. While the occurrence of irAEs in an in-
dividual on combination checkpoint inhibitor therapy is
expected, the dramatic presentation of fulminant T1D
and its potential for other complications is notable and
warrants further consideration.
Autoimmune diabetes is characterized by the devel-
opment of an adaptive immune response against specific
β-cell antigens [18]. Longitudinal studies in patients have
shown that certain autoantibodies, such as anti-insulin
(IAA), anti-islet cell antigen 512 (ICA512), and anti-
glutamic acid decarboxylase (GAD65), define preclinical
disease as they are present in the serum for years prior to
symptom development [19]. They have been shown to be
markers heralding a disease state but do not directly medi-
ate disease progression. This is also true for patients with
latent autoimmune diabetes mellitus in adults (LADA),
which has a slow progression to insulin dependency that
may be predicted by the presence of islet autoantibodies
[20]. Certain cases of T1D are characterized as fulminant
if the patient presents with diabetic ketoacidosis soon after
the onset of hyperglycemic symptoms, has a near normal
HbA1c, and has a low C-peptide level [21]. These patients
typically do not have autoantibodies, the absence of which
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is thought to be indicative of the rapid nature of the dis-
ease pathogenesis [22]. In the case presented here, the
concurrent development of both anti-GAD65 antibodies
and insulin dependency is highly atypical. Indeed, to our
knowledge, it is the first reported case of documented
seroconversion temporally associated with immune check-
point inhibitor therapy.
The clinical presentation of T1D is due to the lack of
endogenous insulin secondary to the destruction of
insulin-producing β-cells in the pancreas. This process
is attributed to infiltration of the pancreatic islets by
autoreactive T cells, causing ‘insulitis’ [23]. The most
widely used model to study this process is the non-
obese diabetic (NOD) mouse. In this population, insu-
litis and overt diabetes spontaneously develop at 20 to
30 weeks of age depending on gender. The NOD mouse
model has been used to assess the relationship between
disease progression and various alleles related to im-
mune regulation, including the pathways targeted by
checkpoint inhibitor therapies, PD-1 and CTLA-4 [24].
Studies in this murine model have implicated a co-
operative relationship between these negative regula-
tory receptors in the pathogenesis of T1D via immune
dysregulation [25, 26]. CTLA-4 has a role in modulat-
ing the survival and function of the regulatory T cell
population, which is responsible for suppressing auto-
reactive T cell activation. The importance of CTLA-4 in
regulating autoimmunity was demonstrated early on in
CTLA-4 knockout mice, in which CD4-predominant
lymphoproliferation develops and results in T cell infil-
tration of multiple organs and early mortality at 3–4
weeks [27]. Indeed, studies by Ansari et al. demon-
strated that CTLA-4 blockade in NOD mice induces
T1D. However, blockade of this pathway was noted to
only induce diabetes in neonates and not in adult mice,
suggesting that the role of CTLA-4 may be limited to
inhibiting the activation of naïve T cells [26]. In con-
trast, PD-1 blockade precipitates diabetes in NOD mice
at any age. This is likely due to PD-1 involvement in
inhibiting both naïve T cells as well as the effector func-
tion of activated autoreactive T cells [26]. Another role
of PD-1 in regulating peripheral tolerance for these
autoreactive T cells is to modulate T cell mobility. Fife et al.
demonstrated that blockade of PD-1 in pre-diabetic NOD
mice inhibits T cell migration, thus promoting the for-
mation of stable conjugates between T cells and antigen
presenting dendritic cells by prolonging their interactions.
The authors concluded that this results in increased T cell
activation and precipitates diabetes in NOD mice [28].
The protective effect of PD-1 has also been suggested in
humans as individuals with T1D have significantly lower
levels of CD4+ T cell PD-1 expression compared to
healthy controls [29]. Taken together, these studies indi-
cate that the CTLA-4 and PD-1 pathways function at
different stages in the development of T cell tolerance to
prevent autoimmune diabetes [30].
This cooperative relationship has been further sup-
ported by studies demonstrating that the risk of T1D is
directly related to the degree of genetic predisposition.
Work by Kochupurakkal et al. in NOD mice demon-
strated that specific strains are protected from develop-
ing T1D after PD-1 blockade by having functional alleles
for Il2 and Ctla4. It was speculated that the functional
Ctla4 allele with the help of IL-2 was sufficient to main-
tain self-tolerance and prevent T1D [25]. While the
exact mechanism remains unclear, similar associations
between the risk of developing T1D and variations in
alleles for CTLA-4 and PD-1 have been identified in
multiple human populations [31–35].
Another genetic predisposition for developing T1D,
and perhaps the most widely studied, relates to the
major histocompatibility complex (MHC) and the asso-
ciated human leukocyte antigen (HLA) molecules. HLA
class I and class II molecules are responsible for present-
ing endogenous and exogenous antigens, respectively, to
T cells and initiating the immune response. Specific vari-
ations in HLA-I and HLA-II molecules are associated
with increased risk of or protection against the develop-
ment of T1D [36]. The incidence of T1D in association
with checkpoint inhibitor therapy has been previously
reported as part of a larger case series, and a few reports
have included HLA typing of the affected individuals
[10–15, 37]. Of the reported cases of immunotherapy-
associated T1D included in Table 1, HLA typing was
performed on eight individuals. Six of these individuals
expressed the HLA-II DR4 haplotype, which is a well-
known risk allele for T1D with an odds ratio (OR) of
5.68 for developing the disease [36, 38]. Our HLA typing
of this patient identified the HLA-I A2 and HLA-II
DQB1*0602 alleles with no evidence of a previously
characterized HLA risk allele for T1D. HLA-II DQB1*0602
is associated with one of the most protective haplotypes for
developing T1D with an OR of 0.03, though this protective
effect seems to be restricted to childhood [38, 39]. We
conclude that the HLA typing for this patient is not
consistent with an immunologic predisposition to the
development of T1D.
In order to investigate this patient’s genetic risk for
developing T1D in more detail, we also conducted a
SNP analysis of 26 different loci previously associated
with the development of T1D and calculated a genetic
risk score (GRS) emulated from Oram et al. [16]. This
GRS summarizes risk-associated variation across the
genome. In this case, the patient’s GRS was 0.2072, a
score that is below the 5th percentile of the T1D cohort
[16]. These findings indicate that this patient did not
have a genetic profile consistent with any known pre-
disposing factors for the development of T1D.
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Table 1 Reported cases of immunotherapy-associated T1D
Study No. of
patients
Patients Age/Sex Past medical history Checkpoint inhibitor therapy Positive serologies Genetics Comments
Gaudy et al. 1 1 44/F None Pembrolizumab Unavailable Unavailable
Martin Liberal et al. 1 1 54/F Mild asthma Ipilimumab and
pembrolizumab
GAD65 70.1 U/mL DRB1*04, DQB1*0302
(HLA A2 DRA DQ8)
Hughes et al. 5 1 55/F Autoimmune thyroid
disease
Nivolumab None A2.1, DR4 Patient had previously
progressed through
ipilimumab
2 83/F Remote smoker Nivolumab GAD65 1.2 U/mL A2.1, DR4




4 58/M Type 2 diabetes mellitus Nivolumab GAD65 13819 U/mL A2.1
5 64/F Autoimmune thyroid disease,
psoriasis
Pembrolizumab None DR4
Okamoto et al. 1 1 55/F Dyslipidemia, gastric ucler Nivolumab None DRB1*04:05,
DQB1*04:01 (DR4)
Miyoshi et al. 1 1 66/F None Nivolumab None DRB1*11:01 13:02:01,
DQB1*03:01:01 06:04:01
Brahmer et al. 1 1 unavailable Unavailable BMS-936559
anti-PDL1 antibody
Unavailable Unavailable
Hoffmann et al. 3 1 70/F None Nivolumab None Unavailable Patient had previously
progressed through
ipilimumab
2 78/F Type 2 diabetes mellitus Nivolumab GAD positive Unavailable
3 58/F None Pembrolizumab GAD, IAA positive Unavailable















This case demonstrates that combination ipilimumab
and nivolumab immunotherapy is capable of inducing
the development of T1D even in those patients with no
discernable risk factors for this disease. These findings
highlight the importance of the PD-1 and CTLA-4 negative
regulatory T cell receptors in the pathogenesis of T1D and
suggest that dual checkpoint blockade may be unleashing
the activation of previously existing islet-reactive T cell
clones in healthy individuals. Given that all reported cases
of checkpoint inhibitor-related T1D have been associated
with anti-PD-1 antibody therapy (Table 1), it seems likely
these islet-reactive T cell clones reside in or near pancreatic
β-islet tissues or their associated draining lymph node
tissues prior to therapy.
In summary, multiple studies have implicated both the
CTLA-4 and PD-1 pathways in the pathogenesis of T1D
and suggest a synergistic relationship between these two
negative regulatory receptors to potentiate autoimmune
disorders. Kochupurrakal et al. concluded that the com-
bined blockade of the CTLA-4 and PD-1 pathways poses
a risk of disrupting peripheral tolerance and generating
T1D [25]. This hypothesis has been supported by studies
of concurrent nivolumab and ipilimumab administration
for the treatment of advanced melanoma, in which the
incidence of grade 3 or 4 irAEs was higher than in trials
of either agent alone [40]. While the HLA-II DR4 haplotype
has been previously reported in cases of immunotherapy-
associated T1D (Table 1), whether these risk alleles predict
for the development of irAEs in patients undergoing check-
point inhibitor immunotherapy remains unclear. Given the
lack of association of any known genetic risk allele for T1D
in the case presented here and the rarity of this complica-
tion in patients undergoing immunotherapy, the use of
established genetic and immunologic screening studies for
T1D prior to initiating a patient on checkpoint inhibitor
immunotherapy may not be indicated. However, this repre-
sents a single case report and more definitive studies will
be necessary to address this issue. Finally, this study
suggests that additional investigation is needed to deter-
mine whether T cell receptor clonotypic analysis to identify
the presence of either peripheral blood or tissue-resident
autoreactive T cell clones may be an effective approach for
predicting which patients are at increased risk for
developing autoinflammatory toxicities while undergo-
ing checkpoint inhibitor immunotherapy.
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